Diatech Pharmacogenetics Announces Investment from TA to Fuel Strategic Growth Initiatives
Diatech Pharmacogenetics (“Diatech” or “the Company”), a leader in pharmacogenetics and cancer precision medicine diagnostics, today announced that TA Associates (“TA”), a leading global private equity firm, has signed a definitive agreement to make a strategic growth investment in the Company. As part of the transaction, minority investor Alto Partners will fully exit its stake in the business. Diatech’s founder and management team will retain majority ownership of the Company, partnering closely with TA.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230426005178/en/
Diatech produces and distributes genomics testing solutions to identify gene mutations and genetic differences that are targets of personalized cancers therapies and that influence patient responses to specific treatments. With these tests, Diatech aims to increase the effectiveness of cancer medicine through personalized diagnosis and treatments.
“We are excited to welcome TA on this journey with us amid a period of great advancement in precision medicine,” said Fabio Biondi, Founder and President of Diatech. “TA offers extensive operational experience and a wide global network that will be critical as we strive to accelerate our international growth and product innovation. We also thank Alto Partners for helping us reach this milestone in our growth journey.”
Founded in 1996, Diatech has demonstrated strong growth in recent years and today is among the first players into the EU market for oncology diagnostics. TA’s investment will support Diatech’s continued development of market-leading diagnostic solutions and reagents in the pharmacogenetics sectors, as well as its global growth initiatives, furthering the Company’s position as a leader in the rapidly expanding molecular diagnostics market.
“As technology improves and there is a greater shift toward precision medicine, continued advancements in the genomic testing landscape are essential,” said Oliva Alberti, CEO of Diatech. “This strategic partnership with TA will allow us to widen the reach of our existing products and services, while also making a meaningful expansion into international markets.”
“Diatech’s comprehensive, market-leading product portfolio highlights the Company’s commitment to a rigorous and differentiated R&D process that consistently drives value creation,” said Lovisa Lander, Director at TA. “We look forward to partnering with Fabio, Oliva, and the entire management team to support Diatech’s international and domestic growth journey.”
“The Company’s proven track record and leading position in its market mean it is well positioned to capitalize on organic and inorganic growth opportunities, expanding its addressable market and extensive product portfolio,” said Birker Bahnsen, Managing Director at TA and head of the firm’s Europe Healthcare Group. “We are thrilled to support Diatech on its next phase of growth.”
“Since our investment in 2021, Diatech has achieved strong organic growth, expanded into new global markets and broadened its product portfolio,” said Enrico Ricotta, Senior Partner at Alto Partners. “It has been a privilege to work with the entire Diatech team and we wish them the best as they build on their continued success in partnership with TA.”
The transaction is expected to close in the second quarter of 2023 pending customary regulatory approval.
Financial terms of the transaction were not disclosed.
About Diatech Pharmacogenetics
Diatech Pharmacogenetics is a leading Italian company in the development, production and commercialization of molecular diagnostic tools for precision oncology medicine. Founded in 1996, the company aims to simplify complex molecular diagnostic procedures into easy end-to-end solutions, from nucleic acid extraction and molecular analysis to final reporting. Diatech has shown strong growth in recent years and today is among the first players in the EU market for the oncology diagnostics market. To learn more, visit www.diatechpharmacogenetics.com
TA Associates (“TA”) is a leading global private equity firm focused on scaling growth in profitable companies. Since 1968, TA has invested in more than 560 companies across its five target industries – technology, healthcare, financial services, consumer and business services. Leveraging its deep industry expertise and strategic resources, TA collaborates with management teams worldwide to help high-quality companies deliver lasting value. The firm has raised $48.6 billion in capital to date and has more than 150 investment professionals across offices in Boston, Menlo Park, Austin, London, Mumbai and Hong Kong. For more information, visit www.ta.com.
About Alto Partners
Alto Partners SGR, an independent company, is controlled by its expert multidisciplinary team to promote and manage private equity funds investing in small-to-medium-sized Italian companies. Alto Partners is a proven experienced, professional and reliable partner in supporting the medium-to-long-term development of our portfolio companies. Together, Alto Partners SGR works alongside industrial families and managers to oversee generational transitions and growth programs. To learn more, visit www.altopartners.it.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230426005178/en/
Communications Manager, TA
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wemade’s MMORPG MIR M Reveals New Content ‘Monster Dungeon’30.5.2023 16:00:00 EEST | Press release
Wemade's MMORPG MIR M: Vanguard and Vagabond showcased new content, "Monster Dungeon," on May 30th. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230530005249/en/ MIR M reveals new “Monster Invasion” content on May 30. (Graphic: Wemade) Users can obtain the "Demonic Stones" of field monsters they have defeated. Each "Demonic Stone" can be used to summon that monster in Monster Dungeon. By defeating all summoned monsters, users can obtain "Essence" items as rewards. "Essence" items can be registered to the Monster Codex to increase character stats. MIR M will be holding the event "Grand Operation Defeat Giant Scarecrow" until the update on June 13th. Users can defeat the Giant Scarecrow that appears in the Ginkgo Valley area to obtain gifts such as "Giant Scarecrow Raid Chests" and "Giant Scarecrow Demonic Stones." By using "Giant Scarecrow Demonic Stones," users can obtain Demonic Stones that can be used to summon boss mons
Q4 Inc. Set to Transform IR Effectiveness with Generative AI on the Q4 Platform30.5.2023 14:30:00 EEST | Press release
Q4 Inc. (TSX: QFOR) (“Q4” or “the Company”), the leading capital markets access platform, is excited to announce progress on pioneering generative artificial intelligence (“AI”) that is purpose built for Investor Relations (“IR”) effectiveness to help automate common tasks and accelerate decision making. By combining AI with the industry’s only end-to-end IR platform, IROs will be able to find insights exclusive to them built on a pool of their own proprietary program data and capital markets data aggregated on the Q4 Platform. “We are embarking on one of the most exciting product cycles in our history,” remarked Darrell Heaps, Founder and CEO of Q4. “Our offerings will unlock tremendous new opportunities for our clients to benefit from the unmatched richness and scale of our proprietary data with the integration of generative AI. The result for clients will simply be effective investor relations and better insights for our investment banking and equity capital markets clients.” In the
Kinaxis RapidResponse Available on Google Cloud Marketplace30.5.2023 14:00:00 EEST | Press release
Kinaxis ® Inc. (TSX: KXS), the authority in driving agility for fast, confident decision-making in an unpredictable world, announced today announced that the market’s leading supply chain management solution, Kinaxis RapidResponse® is available on Google Cloud and in the Marketplace. RapidResponse supports key business processes such as demand and supply planning, integrated business planning, sales and operations planning (S&OP) and inventory management, and delivers end-to-end transparency with its control tower capabilities. Concurrent planning breaks down organizational silos, unifies disparate data under a single all-inclusive data model, and codifies business-wide trust through the continuous alignment of everyone and everything across a company’s end-to-end supply chain. “We’re pleased the Kinaxis platform is now available on Google Cloud,” said Dai Vu, Managing Director, Cloud Marketplace & ISV GTM Initiatives at Google Cloud. “Customers can deploy Kinaxis via the Google Cloud
New Clinical Data on Vuse Illustrates Beneficial Public Health Impact of Tobacco Harm Reduction30.5.2023 13:00:00 EEST | Press release
New results from one of the largest ever vapour product studies, which analysed BAT’s flagship vapour brand Vuse, have been published in the journal of Internal and Emergency Medicine (https://link.springer.com/article/10.1007/s11739-023-03294-9). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230530005321/en/ One of the largest ever vapour product studies compared clinical measurements from exclusive Vuse consumers with smokers (Graphic: Business Wire) The study compared clinical measurements from exclusive Vuse consumers with smokers. The results of the study show that participating Vuse consumers had favourable differences in biomarkers of exposure (BoE) and biomarkers of potential harm (BoPH) relevant to smoking-related diseases when compared to smokers. Vuse users have shown significantly lower biomarkers of exposure for priority cigarette smoke toxicants as defined by the World Health Organization (WHO)iii. The data al
Quectel 5G RG620T modules based on MediaTek T830 gain global certifications to help drive FWA app deployment30.5.2023 13:00:00 EEST | Press release
Quectel Wireless Solutions, a global IoT solutions provider, today announces that its 5G New Radio (NR) modules series, the RG620T has received FCC/ IC/ CE and RCM certifications. The RG620T series is the first 5G module based on the MediaTek T830 System-on-Chip (SoC) to receive all these certifications. The certifications will enable customers to efficiently deploy their 5G fixed wireless access (FWA) devices around the globe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230530005071/en/ Quectel 5G RG620T modules based on MediaTek T830 gain global certifications to help drive FWA app deployment (Graphic: Business Wire) The RG620T delivers an extensive range of cutting-edge features including ultra-high 5G data speeds, quad-core A55 CPU, the latest Wi-Fi 7 connection as well as a series of innovations in antenna frequency band design, flash memory and QuecOpen, making it an ideal solution for the FWA market which demands h
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom